Growth-stage investor and operating executive with a background in corporate finance, strategic partnerships and technology commercialization. Nicole Martin combines operating experience at scale-ups with venture investing across SaaS, fintech and health-tech, advising boards on go-to-market, M&A and capital strategy. Known for sourcing cross-border deals, driving revenue operations and leading due diligence for Series A–C investments.
Growth-stage investor and operating executive with a background in corporate finance, strategic partnerships and technology commercialization. Nicole Martin combines operating experience at scale-ups with venture investing across SaaS, fintech and health-tech, advising boards on go-to-market, M&A and capital strategy. Known for sourcing cross-border deals, driving revenue operations and leading due diligence for Series A–C investments.
Combines operator-first discipline with growth-stage venture investing, favoring SaaS, fintech and health‑tech opportunities where go-to-market and revenue operations drive scalable unit economics. Pursues Series A–C capital allocation with a bias toward cross-border founders, prioritizing companies with clear commercialization paths and repeatable revenue models. Investment decisions blend hands-on diligence on commercial traction and capital strategy with board-level support for M&A and partnerships, emphasizing measurable KPIs, margin improvement, and exit optionality over a 3–7 year horizon.
Combines operator-first discipline with growth-stage venture investing, favoring SaaS, fintech and health‑tech opportunities where go-to-market and revenue operations drive scalable unit economics. Pursues Series A–C capital allocation with a bias toward cross-border founders, prioritizing companies with clear commercialization paths and repeatable revenue models. Investment decisions blend hands-on diligence on commercial traction and capital strategy with board-level support for M&A and partnerships, emphasizing measurable KPIs, margin improvement, and exit optionality over a 3–7 year horizon.
| Trades 4116 | Longs Won 2497/4116 60% | Profit Factor 9.17 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $523,207.03 |
| Average Win $83,993.78 | Best Trade (Jul 13) $18.5M | Sharpe Ratio -14.04 |
| Average Loss -$14,134.53 | Worst Trade (Jul 15) -$31.05M | Z-Score -10.94 (100%) |
| Commissions $0 | Avg. Trade Length 10m 3w 3d | Expectancy $45,395.69 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 83,333 | 75,000 | 66,667 | 58,333 | 50,000 | 41,667 | 33,333 | 25,000 | 16,667 | 8,333 |